East Asian T2D β-Cell Dysfunction Paradigm

The standard Eurocentric model of T2D pathogenesis — insulin resistance compensated initially by increased β-cell response, followed by β-cell exhaustion — does not generalize to East Asian populations. Instead, East Asians (Japanese, Korean, Chinese) develop T2D primarily through reduced insulin secretory capacity, particularly impaired early-phase insulin secretion, with less obesity and insulin resistance compared to age- and sex-matched Caucasians. ¹

Key Evidence

• Lower IGI (insulinogenic index) and HOMA-β (homeostatic model assessment of β-cell function) across NGT (Normal Glucose Tolerance) → IGT (Impaired Glucose Tolerance) → T2D in Japanese vs. Caucasians (Yabe et al. 2015 citing Fukushima et al. 2004, Tripathy et al. 2000). ¹
• Reduced acute insulin response during intravenous glucose tolerance test (IVGTT) confirmed by systematic review and meta-analysis (Kodama et al. 2013). ¹
• Lower homeostatic model assessment of insulin resistance (HOMA-IR) in Japanese throughout all glucose tolerance stages, with less drastic increase from NGT to T2D compared to Caucasians. ¹
• Japanese Americans who adopted Western diet (higher animal fat) show higher diabetes rates than native Japanese, despite comparable calorie intake — suggesting a gene-environment interaction that unmasks latent β-cell vulnerability. ¹

Genetic Architecture

East Asian genome-wide association studies (GWAS) have identified T2D-susceptibility loci predominantly implicating β-cell function:

• KCNQ1 — potassium voltage-gated channel; expressed in insulin-secreting cells; variants identified in Japanese GWAS (Yasuda et al. 2008, Unoki et al. 2008). ¹ — implicates β-cell function, consistent with ancestry-specific T2D genetic architecture.
• UBE2E2 — ubiquitin-conjugating enzyme; expressed in pancreas and insulin-secreting cells, implicated in insulin biosynthesis (Yamauchi et al. 2010). ¹
• C2CD4A/B — function largely unknown (Yamauchi et al. 2010). ¹
• PTPRD, SRR, SPRY2, CDC123 — identified in Han Chinese GWAS (Tsai et al. 2010, Shu et al. 2010); functions in T2D mostly unknown. ¹

Relevance to the PBMC Ancestry Project

The fact that East Asian and European T2D are driven by different primary mechanisms has direct implications for PBMC immune profiling:

1. Different mechanisms, different immune signatures: β-cell dysfunction (primarily a pancreatic defect) and insulin resistance (a systemic metabolic state) likely produce different systemic immune environments. If a cohort contains ancestries that mirror these different mechanisms, PBMC immune features may segregate by ancestry not because of “race” but because the underlying T2D pathophysiology differs.
2. Within-cohort replication: Our prior work (Markelova et al. 2025) demonstrates that this β-cell vs. insulin-resistance dichotomy exists even within a single country (Russia’s Chechen, Tatar, and Yakut populations), with Yakuts (East-Asian-adjacent) showing β-cell-dominant patterns.
3. Therapeutic confound: If treatment guidelines differ by ancestry or T2D mechanism (e.g., sulfonylureas (SUs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) use in Japan vs. metformin first-line in Europe), medication may confound PBMC immune comparisons across groups.

Open Questions

• At what body mass index (BMI) threshold does insulin resistance start to dominate over β-cell dysfunction in East Asians?
• Do East-Asian-ancestry individuals living in Western environments retain β-cell-dominant T2D, or does the mechanism shift toward insulin resistance with lifestyle change?
• Can β-cell dysfunction (a pancreatic phenotype) be detected indirectly through PBMC biomarkers?

Related

• East Asian β-Cell Dysfunction × Ancestry-Associated Immune Differences — synthesis

Sources

• Yabe et al. 2015 — β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians

Footnotes

1. extracted from Yabe et al. 2015 ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹